Neurodegenerative Focus Cantabio specializes in Parkinson’s and Alzheimer’s disease and other neurodegenerative conditions, presenting a clear path for collaboration on brain-targeted therapeutics, biomarkers, and companion diagnostics that align with their small molecule chaperone and BBB-penetrant protein programs.

Preclinical Stage As a preclinical company with growth potential, there are opportunities to engage in early partnerships, research collaborations, and sponsored discovery programs to advance their DJ-1 and tau-targeting efforts toward IND readiness.

Funding & Support Past engagement with MJFF and grant activity indicate openness to funding partnerships and non-dilutive support for select programs, suggesting avenues for co-funded research, grant consulting, and milestone-based collaborations.

Targeted Therapeutics Their focus on small molecule pharmacological chaperones and engineered cell-penetrant proteins offers potential co-development or licensing discussions around novel mechanism-of-action therapies, platform access, and shared IP strategies.

Strategic Partnerships With a lean team and notable traction in in vivo efficacy data, Cantabio may benefit from strategic alliances with larger biotech or pharma partners for clinical development, commercialization planning, and_SCALE_UP manufacturing readiness as they progress.